Evidence map›Paper›PMID 36164399›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Modulation of Drug Resistance by Furanochromones in

Damara F Rodrigues, Nathalie H P B Borges, Carlos Emídio S Nogueira, Josean F Tavares, Daniel Dias Rufino Arcanjo, Humberto M Barreto, José P Siqueira-Junior

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Damara F RodriguesLaboratory of Genetics of Microorganisms, Department of Molecular Biology, Federal University of Paraiba, João Pessoa, PB, Brazil.ORCID https://orcid.org/0000-0002-3253-0490
Nathalie H P B BorgesLaboratory of Genetics of Microorganisms, Department of Molecular Biology, Federal University of Paraiba, João Pessoa, PB, Brazil.ORCID https://orcid.org/0000-0003-4674-8463
Carlos Emídio S NogueiraDepartment of Biological Chemistry, Regional University of Cariri, Crato, CE, Brazil.ORCID https://orcid.org/0000-0002-3554-3780
Josean F TavaresDepartment Pharmaceutical Science, Federal University of Paraíba, João Pessoa, PB, Brazil.ORCID https://orcid.org/0000-0003-0293-2605
Daniel Dias Rufino ArcanjoLaboratory of Functional and Molecular Studies on Physiopharmacology (LAFMOL), Department of Biophysics and Physiology, Federal University of Piauí, Teresina, PI, Brazil.ORCID https://orcid.org/0000-0001-7021-2744
Humberto M BarretoLaboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, PI, Brazil.ORCID https://orcid.org/0000-0001-5054-7555
José P Siqueira-JuniorLaboratory of Genetics of Microorganisms, Department of Molecular Biology, Federal University of Paraiba, João Pessoa, PB, Brazil.ORCID https://orcid.org/0000-0001-7966-2506

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Khellin and visnagin are natural furanochromones that photoreact with DNA. Khellin has been used in the treatment of vitiligo and psoriasis, as well as in the treatment of angina pectoris and asthma due to its potent action as a coronary vasodilator and antispasmodic agent. The present study aimed to investigate whether the compounds khellin and visnagin act as inhibitors of NorA protein, an efflux pump overproduced by the strain of

Identifiers

PMID36164399
PMCPMC9509268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.